Bextra Arthritis Drug Publications

The following publications on the arthritis drug Bextra has been provided by the U.S. Food and Drug Administration, public interest groups, and Weitz & Luxenberg, PC.

   • Bextra Labeling: Includes documents describing the clinical pharmacology, NDC codes with respective trade names, and current product label.

   • FDA Bextra Letters: These are letters from the FDA issuing warnings and safety alerts.

   • FDA Bextra Warnings: These are warnings from the manufacturer and FDA signifying warnings concerning the use of the drug Bextra.

   • FDA Public Comments: This section includes comments from the public about the drug Bextra.

Weitz & Luxenberg is no longer accepting Bextra cases.

see also:

Letters FDA Bextra Letters - Without a Bextra recall, Bextra is still deadly
Though no Bextra recall, Bextra, these letters show, can be dangerous.

Labeling Arthritis Drug Bextra Labeling information
official documents on the labeling of the arthritis drug Bextra

Breaking news Breaking Lawsuit Resource Center: Bextra Breaking News
Bextra (Valdecoxib) Resource Center: Bextra Breaking News